Galectin Therapeutics FY13 Loss Widens - Quick Facts

(RTTNews) - Galectin Therapeutics Inc. (GALT) posted fiscal 2013 net loss applicable to common stock of $21.9 million or $1.30 per share, wider than $10.9 million or $0.72 per share in the prior year period. The increase in net loss applicable to common stock is largely due to an $8.8 million or $0.53 per share one-time, non-cash charge related to modification of certain warrants recorded in the second quarter of 2013 and an unrelated one-time, non-cash stock compensation charge of $1.0 million or $0.06 per share recorded in the third quarter of 2013.

Three analysts expected loss of $1.29 per share for fiscal 2013.

Total other income for the period was $16 thousand, down from $224 thousand last year.